Does Liquidia, Corp. pay dividends?
LISI Group owns Hi-Shear Corporation outright, having successfully acquired the prominent aerospace fastener manufacturer to integrate it into its specialized industrial aerospace division. Operating under the corporate banner of LISI Aerospace, Hi-Shear continues to manufacture high-precision fasteners, structural components, and specialized assembly parts for global commercial aircraft and defense programs. The parent organization oversees all strategic manufacturing operations, quality standards, and international distribution channels for the acquired business.
Related FAQs
Liquidia Corporation (NASDAQ: LQDA) trades at $83.85 per share, reflecting a market capitalization of approximately $7.46 billion.
Participating in the global stock market can generate substantial financial profitability over the long term, driven by corporate dividend distributions, capital appreciation, and compound earnings growth.
Equity research analysts tracking Liquidia Corporation generally maintain favorable consensus ratings, driven by strong commercial momentum surrounding its pulmonary hypertension treatments, innovative PRINT drug delivery technology, and positive leg...
Liquidia Corporation is a biopharmaceutical enterprise dedicated to developing and commercializing innovative therapies for the treatment of pulmonary hypertension and other complex respiratory diseases.
Liquidia Corporation (traded on the NASDAQ under the ticker LQDA) trades actively during regular market sessions, reflecting the biopharmaceutical enterprise's clinical and commercial progress in developing proprietary polymer nanoparticle therapies ...
Liquidia Corporation shares, which trade under the public ticker symbol LQDA on the Nasdaq Global Select Market, can be purchased and sold through almost any reputable online stock brokerage, retail investment application, or full-service financial a...
Liquidia Corporation (LQDA) reports financial results reflecting its transition into a commercial-stage biopharmaceutical company anchored by its innovative dry powder inhalation pipeline, including Yutrepia for pulmonary arterial hypertension.
Yes, LUKOIL, one of Russia's largest multinational energy and oil corporations, has been subjected to significant international economic penalties and restrictive measures.
Liquidia Corporation (LQDA) is a biopharmaceutical company headquartered in Morrisville, North Carolina, that focuses on developing and commercializing therapies for patients with severe respiratory and vascular diseases, particularly rare cardiopulm...
Consensus analyst price targets for Liquidia Corporation (NASDAQ: LQDA) average approximately $22.00, with high-end biotechnology projections extending up to $30.00.
LQDA is the official Nasdaq stock market ticker symbol for Liquidia Corporation, a specialized biopharmaceutical enterprise dedicated to developing and commercializing innovative therapeutic products for patients suffering from rare cardiopulmonary d...
Liquidia Corporation (LQDA) financial updates highlight significant corporate progression as commercial revenues scale up following regulatory and legal milestones for its leading pulmonary therapies.
Liquidia operates primarily as a commercial-stage and clinical-stage biopharmaceutical enterprise that has historically navigated net operating losses typical of high-growth pharmaceutical research firms, though its scaling product revenues continue ...
Liquidia Corporation attracts considerable attention from biotechnology and specialty pharmaceutical investors due to its innovative treatment portfolio for pulmonary hypertension and its proprietary PRINT particle engineering technology.
Liquidia Corporation (NASDAQ: LQDA) is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapies for patients suffering from severe respiratory and vascular diseases, with a primary concentration on pulmon...
As of the close of the most recent trading session on July 31, 2026, the stock price for Liquidia Corporation (LQDA) was $84.11. The stock had experienced a decline of approximately 3.
Liquidia Corporation (LQDA) is followed closely by a specialized group of healthcare and biotechnology equity research analysts from prominent Wall Street and boutique investment firms.
The stock ticker symbol LQDA represents Liquidia Corporation, which is a biopharmaceutical enterprise publicly traded on the NASDAQ stock exchange specializing in the development of innovative therapeutics utilizing proprietary printing technology.
Liquidia Corporation, a biopharmaceutical enterprise focused on the development and commercialization of innovative products targeting cardiopulmonary diseases using proprietary printing technology, has its corporate headquarters located in Morrisvil...
Financial analysts and market forecasters maintain highly favorable stock predictions and price targets for Liquidia Corporation, reflecting strong commercial momentum following the successful rollout and adoption of its inhaled prostacyclin therapy.
Liquidia Corporation (traded under the ticker LQDA) is a biopharmaceutical company evaluated primarily through consensus research coverage from healthcare equity analysts rather than traditional sovereign or corporate bond rating agencies.